Amgen Inc.

AMGNleader

Amgen is one of the world's largest biotechnology companies, pioneering the development of biologic medicines since the 1980s. Its acquisition of Horizon Therapeutics strengthened its rare disease portfolio, while MariTide, its obesity drug candidate, represents a potential blockbuster entry into the weight-loss market.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($33.4B)

Data statis (memuat keuangan langsung…)

General Medicine (Prolia, Repatha, Evenity) (35%)

Inflammation (Enbrel, Otezla) (20%)

Oncology/Hematology (25%)

Horizon Therapeutics Portfolio (20%)

Komposisi segmen dan pelanggan utama

Detail produk

Repatha/Prolia/Xgeva30%

PCSK9 inhibitor for cholesterol and bone-targeting antibodies for osteoporosis/cancer

Enbrel20%

Anti-TNF biologic for rheumatoid arthritis and psoriasis

Tezspire/Lumakras25%

Next-gen asthma biologic and first KRAS inhibitor for lung cancer

Hubungan Rantai Pasok

Pesaing

AbbVie Inc.

Immunology biologics (Enbrel vs Humira)

Dampak: Long-standing rivalry

Eli Lilly and Company

Obesity and cardiometabolic drugs

Dampak: Emerging obesity competition

Pfizer Inc.

Biosimilars and inflammation

Dampak: Broad pharma competition

Konteks makro dan pasar

제약 / 바이오Berita sektor

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Katalis mendatang

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok Amgen Inc..

Info Perusahaan

Kantor Pusat

Thousand Oaks, California, USA

Didirikan

1980

Karyawan

27,000+

Situs Web

amgen.com

Gambaran umum sektor — 제약 / 바이오

Berita sektor